Metabolic associated fatty liver disease increases coronavirus disease 2019 disease severity in nondiabetic patients
Journal of Gastroenterology & Hepatology
; 36(1):204-207, 2021.
Article
in English
| MEDLINE | ID: covidwho-1032413
ABSTRACT
BACKGROUND AND AIM:
Coronavirus disease 2019 (COVID-19) has attracted increasing worldwide attention. While diabetes is known to aggravate COVID-19 severity, it is not known whether nondiabetic patients with metabolic dysfunction are also more prone to more severe disease. The association of metabolic associated fatty liver disease (MAFLD) with COVID-19 severity in nondiabetic patients was investigated here.METHODS:
The study cohort comprised 65 patients with (i.e. cases) and 65 patients without MAFLD (i.e. controls). Each case was randomly matched with one control by sex (11) and age (+/-5 years). The association between the presence of MAFLD (as exposure) and COVID-19 severity (as the outcome) was assessed by binary logistic regression analysis.RESULTS:
In nondiabetic patients with COVID-19, the presence of MAFLD was associated with a four-fold increased risk of severe COVID-19;the risk increased with increasing numbers of metabolic risk factors. The association with COVID-19 severity persisted after adjusting for age, sex, and coexisting morbid conditions.CONCLUSION:
Health-care professionals caring for nondiabetic patients with COVID-19 should be cognizant of the increased likelihood of severe COVID-19 in patients with MAFLD.
Full text:
Available
Collection:
Databases of international organizations
Database:
MEDLINE
Type of study:
Prognostic study
Language:
English
Journal:
Journal of Gastroenterology & Hepatology
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS